The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
Busca, A., Salmanton-García, J., Corradini, P., Marchesi, F., Cabirta, A., Di Blasi, R., Dulery, R., Lamure, S., Farina, F., Weinbergerová, B., Batinić, J., Nordlander, A., López-García, A., Drgoňa, Ľ., Espigado-Tocino, I., Falces-Romero, I., García-Sanz, R., García-Vidal, C., Guidetti, A., Khanna, N., Kulasekararaj, A., Maertens, J., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Cornely, O. A., Pagano, L., COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP, <<BLOOD ADVANCES>>, 2022; 6 (7): 2427-2433. [doi:10.1182/bloodadvances.2021005616] [http://hdl.handle.net/10807/217384]
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Di Blasi, Roberta;Pagano, LivioConceptualization
2022
Abstract
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
